ProMIS Neurosciences Inc PMN

Change?

[bball67]

Three high-quality new board members, New COO, Boston Group at 40%+, Boston Group taking an active role, Williams and Goldstein changing chairs is not the final move, expect new Chief Medical Officer and new CEO, Company targeting a $650 market cap of a comparable biopharma peer, not thinking of financing until mid to late 2022,  preparation has begun for huge document delivery for FDA clinical trial filing, hoping for a possible live conference call for Q3, and much more. News flow, NASDAQ listing and new analyst coverage are all potential catalysts. It is hard to say what specifically will be "the catalyst" for a breakout. Now at 1.3M shares, confidence inspired by Boston billionaires going all in with Promis and making the necessary moves and changes. Stay positive-this is going to pay off.

[BottomBroker]

I like the way you think, bball. And I sure hope you're right. 

[DavidKingCanada]

650 Cap will be a 10 fold jump from where it is sitting now. Let's hope your right, stay Positive! 

[retiredcop]

Preparing for a Huge package delivery to the fda and why are you so confident that clinicals will be done in the USA. I sure would like to know where you are getting your updates from.  ' before they can submit anything to any one they have to create     The cell line and these are living cells so highly unpredictable. .. Test the cell Line safety on 2 different animals and

[retiredcop]

That could be why the lastest on the company website is targeting 2 half of 2022

[bball67]

The documentation requirements for the FDA may be 20-30 thousand pages. Lets just assume I was told that. Much of that documentation is independent of the success of the cell line and safety. Of course those two items you mentioned are key pieces of the total documentation. Beginning to identify what documentation is necessary and beginning to pull it together is what the Company should be doing

[Bookworm28]

I'll 2nd bottombroker's comment. PMN needs to do a major mgmt overhall, and initiate a major injection of superstar talent, if they hope to have any chance at reviving interest and confidence in what they are attempting to do. This is complex biology, and assembling the best and the brightest is requisite to earning any respect in the market.